Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TIPARP | Q7Z3E1 | 8/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | KRAS | P01116 | 1/20 | 0.32 |
| ▸ | TRPC5 | Q9UL62 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24417510 | 1.00 | TIPARP (0.40) | TIPARPPOLBP2RX7KRASTRPC5 | |
| SCHEMBL24417508 | 0.94 | POLB (0.36) | TIPARPPOLBTRPC5ALDH1A1CHRM4 | |
| SCHEMBL29618633 | 0.94 | POLB (0.36) | TIPARPPOLBTRPC5ALDH1A1CHRM4 | |
| SCHEMBL29618696 | 0.91 | POLB (0.36) | TIPARPPOLBTRPC5ALDH1A1CHRM4 | |
| SCHEMBL24417963 | 0.91 | POLB (0.36) | TIPARPPOLBTRPC5ALDH1A1CHRM4 | |
| SCHEMBL24417967 | 0.90 | TIPARP (0.36) | TIPARPPOLBTRPC5ALDH1A1CHRM4 | |
| SCHEMBL29618627 | 0.90 | TIPARP (0.36) | TIPARPPOLBTRPC5ALDH1A1CHRM4 | |
| SCHEMBL24417582 | 0.89 | TIPARP (0.35) | TIPARPPOLBTRPC5ALDH1A1CHRM4 | |
| SCHEMBL24417844 | 0.89 | TIPARP (0.38) | TIPARPPOLBTRPC5ALDH1A1KCNH2 | |
| SCHEMBL29618564 | 0.89 | TIPARP (0.35) | TIPARPPOLBTRPC5ALDH1A1CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12202818-B2 | Compounds and methods for CD73 modulation and indications therefor | Opna Bio SA (CH) | 2025-01-21 | — | — | US | disclosed |
| EP-4139296-B1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2024-09-18 | — | — | EP | disclosed |
| US-20240174640-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2024-05-30 | — | — | US | disclosed |
| US-11807626-B2 | Compounds and methods for CD73 modulation and indications therefor | Opna Bio SA (CH) | 2023-11-07 | — | — | US | disclosed |
| US-20220144805-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12202818-B2 | Compounds and methods for CD73 modulation and indications therefor | ENTPD5, ENTPD1, ADORA2A | TIPARP 2121/4885POLB 1748/4885P2RX7 48/4885 |
| US-20240174640-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | ENTPD5, ENTPD1, ADORA2A | TIPARP 2121/4885POLB 1748/4885P2RX7 48/4885 |
| US-11807626-B2 | Compounds and methods for CD73 modulation and indications therefor | ENTPD5, ENTPD1, ADORA2A | TIPARP 2121/4885POLB 1748/4885P2RX7 48/4885 |
| US-20220144805-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | ENTPD5, ENTPD1, ADORA2A | TIPARP 2143/4885POLB 1741/4885P2RX7 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.